MAWD Pathology Group

What MAWD Pathology Group does

MAWD Pathology Group, Inc. is a physician-owned, for-profit C corporation providing anatomic and clinical pathology and laboratory diagnostic services across the Midwest. Founded in 1969 in the Kansas City region and headquartered in Lenexa, Kansas, the company employs 250+ staff and 55+ board-certified pathologists with subspecialty expertise in molecular genetic pathology, dermatopathology, hematopathology, cytopathology, oral and maxillofacial pathology, gastrointestinal pathology, breast pathology, and gynecologic pathology. MAWD serves 20+ regional hospitals, 13 surgery and endoscopy centers, and 900+ physician offices, processing specimens for more than 250,000 patients annually. Following its April 2022 acquisition of Boyce & Bynum Pathology Professional Services, the group operates across three states.

The company's core technology is a network of in-house laboratories running advanced molecular and immunohistochemistry platforms, including FISH, RT-PCR, next-generation sequencing (52-gene Oncomine Focus panel), BRCA 1/2 somatic mutation analysis, IHC, and flow cytometry, all operating under CAP accreditation and CLIA certification. The FDA issued an Emergency Use Authorization in October 2023 for MAWD's in-house SARS-CoV-2 Dual Target RT-PCR test. Specimens are collected through MAWD's own courier network and results are delivered through the MAWD Connect client portal. All malignant and complex diagnoses undergo a mandatory second-pathologist concurrence review, with 24-48 hour standard turnaround times.

MAWD's revenue model is fee-for-service per specimen, with the group billing for anatomic and clinical pathology services either directly or, as of March 31, 2025, through Labcorp for certain clinical and women's health tests not performed in-house. The company also earns professional fees through medical directorship arrangements with hospitals and offers direct-to-patient cash-pay COVID-19 PCR ($149) and antibody ($50) testing. Pricing for core pathology services is negotiated with commercial payors, Medicare, and Medicaid, and MAWD transitioned to in-house billing for dates of service on or after October 1, 2022.

Name

MAWD Pathology Group

Legal name

MAWD Pathology Group, Inc.

Website

https://mawdpathology.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

251–500 employees

Short description

MAWD Pathology Group is a physician-owned pathology and laboratory services provider operating across the Midwest, serving 20+ hospitals, 13 surgery centers, and 900+ physician offices with 55+ board-certified subspecialty pathologists.

Ownership category

akta.pro rank

Product category

Pathology and Laboratory Diagnostic Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industries

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

Keywords

• Pathology services
• Clinical laboratory testing
• Molecular diagnostics
• Anatomic pathology
• Surgical pathology services

Headquarters

HQ city

North Kansas City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Anatomic Pathology Services: MAWD bills for pathology and cytology services performed by its pathologists, including examination of biopsies, pap smears, blood specimens, and surgical specimens. Services are ordered by physicians and billed separately from the ordering provider's charges.
2. Clinical Pathology Services: MAWD provides clinical laboratory testing services. As of March 31, 2025, MAWD has partnered with Labcorp for clinical and women's health testing not performed in-house, with Labcorp handling performance and billing for those specific tests.
3. COVID-19 Testing: Cash-pay COVID-19 PCR testing at $149.00 per test and antibody testing at $50.00 per test offered directly to patients.
4. Medical Directorship Services: MAWD serves as medical director for hospitals and provides pathology oversight services, generating professional fee revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

MAWD Pathology Group is a physician-owned pathology and laboratory services provider delivering comprehensive anatomic and clinical pathology diagnostics, including histopathology, cytology, immunohistochemistry, flow cytometry, and molecular diagnostics. The group operates multiple subspecialty practices spanning dermatopathology, oral and maxillofacial pathology, breast, gastrointestinal, gynecologic, and hematopathology services for hospitals, surgery centers, and physician offices across the Midwest. In-house molecular capabilities include FISH, RT-PCR, and a 52-gene Oncomine Focus Next Generation Sequencing (NGS) assay for oncology and personalized medicine applications.

Product overview

MAWD Pathology Group is a physician-owned pathology and laboratory services provider offering a comprehensive portfolio of diagnostic services. The core offerings include Anatomic Pathology (histopathology, cytology, IHC, flow cytometry) and Clinical Pathology (blood banking, hematology, chemistry, microbiology). Sub-specialty services include Molecular Pathology (oncology NGS testing, BRCA analysis), Dermatopathology, Oral and Maxillofacial Pathology, Breast Pathology, Gastrointestinal Pathology, Gynecologic Pathology, and Hematopathology. MAWD Connect serves as the client-facing portal for test ordering and results. As of March 2025, MAWD partners with Labcorp for clinical and women's health testing not performed in-house. COVID-19 PCR and antibody testing is available at $149 and $50 cash price respectively.

Differentiator

Problem solved

Functional benefit

Products and services

• Anatomic Pathology Services Comprehensive anatomic pathology services including histopathology, cytology, immunohistochemistry (IHC), flow cytometry, and pathology consultation across multiple subspecialties for hospitals, surgery centers, and physician offices.
• Clinical Pathology Services Clinical laboratory services including blood banking and transfusion medicine, hematology, chemistry, and microbiology testing for hospital and reference laboratory clients.
• Molecular Pathology In-house molecular diagnostics laboratory offering oncology testing including HER2 amplification, KRAS/BRAF/NRAS mutation analysis, EGFR mutation analysis, ALK/ROS1 translocation detection, BRCA 1/2 NGS, and Next Generation Sequencing (NGS) assays for cancer diagnostics and personalized medicine.
• Oncology Testing Panel Comprehensive cancer diagnostics including breast cancer (HER2 by FISH), colorectal cancer (KRAS, BRAF, NRAS, MSI, MMR), lung cancer (EGFR, ALK, ROS1), melanoma (BRAF), and the Oncomine Focus 52-gene NGS assay.
• Oral and Maxillofacial Pathology Specialized diagnosis of conditions affecting the oral cavity and craniofacial region including inflammatory, immune-mediated, and neoplastic conditions such as autoimmune diseases, oral and oropharyngeal cancer, jaw tumors, and salivary gland tumors.
• Dermatopathology Expert skin pathology diagnostics provided through MAWD Derm Path, serving dermatologists and healthcare providers with specialized tissue analysis services.
• COVID-19 Testing PCR testing for current SARS-CoV-2 infections and serology antibody testing for signs of previous infection, with cash pricing of $149 for PCR and $50 for antibody testing.
• SARS-CoV-2 Dual Target RT-PCR Test FDA Emergency Use Authorized RT-PCR test for detection of SARS-CoV-2 with dual target design for enhanced accuracy, used in MAWD's COVID-19 testing service line.
• MAWD Connect Client Portal Secure online client portal providing access to test directory, results viewing, billing management, supply ordering, and specimen handling resources for healthcare providers.

Quantifiable outcome

• Over 250,000 patients served annually across the Midwest
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• LabcorpcoreTechnology or Integration · 31 March 2025As of March 31, 2025, MAWD partnered with Labcorp for the performance and billing of clinical and women's health testing not offered directly in-house. Labcorp serves as the performing and billing laboratory for these specific tests, while MAWD continues to handle anatomic and molecular pathology services directly. This partnership extends MAWD's test menu while leveraging Labcorp's comprehensive clinical laboratory capabilities.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NeoGenomics: Oncology-focused molecular pathology and diagnostic services company offering NGS, IHC, and cytogenetic testing to community hospitals and oncologists. Comparable to MAWD's molecular pathology franchise (Oncomine Focus, BRCA 1/2, FISH oncology panels) and the same community-hospital customer base.
• ProPath: Physician-owned pathology practice providing anatomic pathology, molecular diagnostics, and subspecialty expertise to hospitals and referring physicians. Comparable to MAWD on physician-owned model, subspecialty bench, and B2B provider sales motion.
• PathGroup: One of the largest physician-owned pathology groups in the United States, offering anatomic, clinical, and molecular pathology to hospitals and physician practices across multiple states. Closely comparable to MAWD on ownership model, subspecialty coverage, regional-to-multi-state footprint, and in-house molecular platform.

Emerging players

• Histo-Scientific Research Laboratories (HSRL): Specialized dermatopathology and anatomic pathology laboratory serving referring physicians in the Mid-Atlantic. Comparable niche subspecialty lab model relevant to MAWD's dermatopathology and oral pathology growth verticals.
• Dermpath Diagnostics: Specialized dermatopathology laboratory serving dermatology practices with high-volume skin biopsy interpretation. Comparable to MAWD's dermatopathology service line (mawddermpath.com) and overlapping on subspecialty skin pathology delivery.

Broad incumbents

• Sonic Healthcare USA: Subsidiary of Sonic Healthcare operating U.S. anatomic and clinical pathology businesses including CBLPath and other regional labs. Comparable to MAWD on anatomic pathology services, multi-state footprint, and provider-referral business model.
• ARUP Laboratories: Hospital-owned national reference laboratory associated with the University of Utah, providing esoteric and subspecialty testing to hospitals and health systems. Comparable to MAWD on subspecialty anatomic and molecular test menu and on hospital-system customer profile.
• Laboratory Corporation of America (Labcorp): National clinical and anatomic pathology reference lab, and direct partner of MAWD since March 31, 2025 for clinical and women's health testing. Comparable in test menu breadth and serves many of the same hospital and physician customers.
• AmeriPath: Anatomic pathology practice within the Quest Diagnostics network, providing subspecialty diagnostic services to hospitals, surgery centers, and physicians nationwide. Comparable to MAWD on subspecialty anatomic pathology and hospital/ASC customer base.
• Quest Diagnostics: Largest U.S. clinical laboratory network offering routine and esoteric testing nationwide. Competes with MAWD on clinical pathology volume, hospital reference lab contracts, and increasingly on subspecialty anatomic and molecular services (e.g., AmeriPath).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MAWD Pathology Group